We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
HeartSciences Inc | NASDAQ:HSCSW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.045 | 0.022 | 0.06 | 0 | 00:00:00 |
550 Reserve Street | Suite 360
Southlake, Texas 76092
Dial: 682.237.7781
danielle.watson@heartsciences.com
December 19, 2024
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100F Street, N.E.
Washington, D.C. 20549
Attn: Jane Park
Re: | HeartSciences Inc. fka Heart Test Laboratories, Inc. | |
Registration Statement on Form S-1 | ||
Filed June 7, 2023 | ||
File No. 333-272501 |
Dear Sir or Madam:
HeartSciences Inc. fka Heart Test Laboratories, Inc., a Texas corporation (the “Company”), hereby requests, pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), that, effective as of the date first set forth above, the U.S. Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-272501), together with all amendments and exhibits thereto (collectively, the “Registration Statement”). The Registration Statement, as amended, was originally filed on June 7, 2023 and has not been declared effective by the Commission.
The Company confirms that no securities have been, or will be, issued or sold pursuant to the Registration Statement or the public offering prospectus contained therein.
The Company further requests that, in accordance with Rule 457(p) of the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.
Should any member of the Commission’s staff have any questions concerning the enclosed materials or desire any further information or clarification in respect of this request to withdraw, please contact our counsel, Jonathan Shechter, Esq. at 212-335-0465 or js@foleyshechter.com or Sasha Ablovatskiy, Esq. at 212-335-0466 or sablovatskiy@foleyshechter.com.
Sincerely, | ||
HEARTSCIENCES INC. | ||
By: | /s/ Danielle Watson | |
Name: | Danielle Watson | |
Title: | Chief Financial Officer |
Cc: | United States Securities and Exchange Commission |
Jane Park | |
Loan Lauren Nguyen | |
HeartSciences Inc. | |
Andrew Simpson, Chief Executive Officer Danielle Watson, Chief Financial Officer |
1 Year HeartSciences Chart |
1 Month HeartSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions